Greg Tourangeau, Principal Accounting Officer at Fulcrum Therapeutics ($FULC), made one open market sale of shares in the last year, totaling about $2,520. His most recent sale occurred on May 8, 2025. These Fulcrum Therapeutics insider sales rank 11,475th out of 11,678 individuals in our database, well below the average of $8.6 million across 6.4 transactions. Tourangeau Greg recorded no open market purchases in the last 365 days.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 2, 2026 | Fulcrum Therapeutics, Inc. | $FULC | Tourangeau Greg | Principal Accounting Officer | A | Stock Option (right to buy) | 57000 | $0.00 | 57,000.0000 | 62,597,000 | 9999.99% | 0.09% |
| May 8, 2025 | Fulcrum Therapeutics, Inc. | $FULC | Tourangeau Greg | Principal Accounting Officer | S | Common Stock | 498 | $5.06 | 14,062.0000 | 61,984 | 3.42% | 0.80% |
| Jan. 24, 2025 | Fulcrum Therapeutics, Inc. | $FULC | Tourangeau Greg | Principal Accounting Officer | A | Stock Option (right to buy) | 76120 | $0.00 | 76,120.0000 | 61,984 | 9999.99% | 100.00% |
| May 7, 2024 | Fulcrum Therapeutics, Inc. | $FULC | Tourangeau Greg | Principal Accounting Officer | S | Common Stock | 236 | $7.76 | 11,571.0000 | 61,310 | 2.00% | 0.38% |
| March 8, 2024 | Fulcrum Therapeutics, Inc. | $FULC | Tourangeau Greg | Vice President, Finance | S | Common Stock | 4884 | $11.72 | 11,807.0000 | 61,310 | 29.26% | 7.97% |
| Jan. 26, 2024 | Fulcrum Therapeutics, Inc. | $FULC | Tourangeau Greg | Vice President, Finance | A | Stock Option (right to buy) | 10000 | $0.00 | 10,000.0000 | 61,310 | 9999.99% | 16.31% |
| Jan. 26, 2024 | Fulcrum Therapeutics, Inc. | $FULC | Tourangeau Greg | Vice President, Finance | A | Stock Option (right to buy) | 83820 | $0.00 | 83,820.0000 | 61,310 | 9999.99% | 100.00% |